Which treatment is most likely to be used first for a patient with ITP experiencing acute bleeding?

In the case of a patient with immune thrombocytopenic purpura (ITP) experiencing acute bleeding, intravenous immunoglobulin (IVIG) is often the first treatment used. IVIG works by increasing platelet counts and providing a rapid response, which is critical in managing acute bleeding situations. It helps to neutralize the autoantibodies that are destroying platelets and can also promote platelet release from the spleen.

Using IVIG is particularly advantageous because it acts quickly, providing a temporary boost in platelet levels that can help control bleeding while waiting for more definitive treatments or the body’s own processes to stabilize the platelet count. Other interventions, such as platelet transfusions, are not effective in ITP since the underlying problem is the destruction of platelets rather than a deficiency in production. Therefore, simply adding more platelets would not resolve the issue. Routine observation is not appropriate in cases of acute bleeding, as prompt intervention is necessary to address the immediate risk of hemorrhage.